DaVita (NYSE:DVA) Sets New 1-Year High – Time to Buy?

DaVita Inc. (NYSE:DVA) hit a new 52-week high during trading on Monday . The stock traded as high as $172.17 and last traded at $172.71, with a volume of 12210 shares traded. The stock had previously closed at $170.28.

Analysts Set New Price Targets

Several research firms have issued reports on DVA. Barclays upped their price target on shares of DaVita from $150.00 to $164.00 and gave the company an “equal weight” rating in a research report on Thursday, October 31st. Truist Financial lifted their price objective on DaVita from $165.00 to $175.00 and gave the company a “hold” rating in a research note on Monday, October 7th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $161.80.

DaVita Stock Performance

The business has a fifty day moving average price of $158.32 and a 200-day moving average price of $154.01. The stock has a market capitalization of $14.26 billion, a P/E ratio of 18.74, a P/E/G ratio of 0.82 and a beta of 0.92. The company has a quick ratio of 1.33, a current ratio of 1.37 and a debt-to-equity ratio of 15.78.

DaVita (NYSE:DVA) last announced its quarterly earnings results on Tuesday, October 29th. The company reported $2.59 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.76 by ($0.17). The company had revenue of $3.26 billion for the quarter, compared to analysts’ expectations of $3.25 billion. DaVita had a net margin of 6.53% and a return on equity of 88.18%. The business’s revenue was up 4.6% compared to the same quarter last year. During the same period in the previous year, the business earned $2.85 EPS. On average, sell-side analysts expect that DaVita Inc. will post 9.71 EPS for the current year.

Institutional Investors Weigh In On DaVita

A number of large investors have recently made changes to their positions in DVA. ProShare Advisors LLC grew its position in shares of DaVita by 3.7% during the 2nd quarter. ProShare Advisors LLC now owns 7,537 shares of the company’s stock valued at $1,044,000 after acquiring an additional 268 shares during the period. Public Sector Pension Investment Board bought a new position in shares of DaVita in the second quarter worth about $235,000. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp lifted its position in shares of DaVita by 58.5% during the 2nd quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 10,280 shares of the company’s stock valued at $1,424,000 after buying an additional 3,794 shares in the last quarter. AXA S.A. grew its stake in shares of DaVita by 66.8% during the 2nd quarter. AXA S.A. now owns 26,268 shares of the company’s stock valued at $3,640,000 after acquiring an additional 10,521 shares during the period. Finally, MBB Public Markets I LLC bought a new stake in DaVita during the 2nd quarter worth approximately $582,000. 90.12% of the stock is currently owned by institutional investors.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.